The Latest Cardiac and Vascular News
Dr. Romano will succeed Dr. Giles Campion, CMO and Head of R&D, following his retirement by year-end LONDON–(BUSINESS WIRE)–Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing […]
Company to host fourth quarter conference call and webcast today at 8 a.m. EDT / 12 p.m. GMT LONDON–(BUSINESS WIRE)–Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by […]
LONDON–(BUSINESS WIRE)–Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced the appointment of J.P. Gabriel as Chief Technical Operations Officer […]
LONDON–(BUSINESS WIRE)–Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today reported its financial results for the third quarter ended September 30, […]
– Assessment showed participants who received a single dose of SLN360 maintained median reductions over 80% over a five-month period November 05, 2022 10:30 AM Eastern Daylight Time LONDON–(BUSINESS WIRE)–Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and […]
LONDON–(BUSINESS WIRE)–Silence Therapeutics plc (Nasdaq: SLN) (“Silence”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced the pricing of an underwritten […]
LONDON–(BUSINESS WIRE)–Silence Therapeutics plc (Nasdaq: SLN), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that it will receive a $2.0 […]
– SLN360 reduced Lp(a) – a key genetic risk factor for heart disease – by up to 98% with reductions of up to 81% persisting at 150 days – Results were simultaneously published in The Journal of the American Medical Association (JAMA) […]
Mark Rothera steps down as President and CEO LONDON–(BUSINESS WIRE)–Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (“siRNA”) therapeutics for the treatment of diseases with […]
SLN360, an investigational siRNA to reduce risk of Lp(a)-mediated cardiovascular disease, was safe and well tolerated in the study SLN360 significantly lowered Lp(a) in a dose-dependent manner up to 98% with reductions of up to 81% persisting at 150 days […]
